nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PSMA1—mouth—larynx cancer	0.0776	0.109	CbGeAlD
Bortezomib—PSMA1—epithelium—larynx cancer	0.0451	0.0633	CbGeAlD
Bortezomib—CTSG—trachea—larynx cancer	0.0416	0.0583	CbGeAlD
Bortezomib—PSMD1—trachea—larynx cancer	0.0335	0.047	CbGeAlD
Bortezomib—PSMA1—thyroid gland—larynx cancer	0.0316	0.0443	CbGeAlD
Bortezomib—PSMD2—trachea—larynx cancer	0.0297	0.0416	CbGeAlD
Bortezomib—PSMB8—trachea—larynx cancer	0.0295	0.0414	CbGeAlD
Bortezomib—PSMD1—thyroid gland—larynx cancer	0.0265	0.0372	CbGeAlD
Bortezomib—PSMB5—trachea—larynx cancer	0.0261	0.0365	CbGeAlD
Bortezomib—PSMD2—thyroid gland—larynx cancer	0.0235	0.0329	CbGeAlD
Bortezomib—PSMB8—thyroid gland—larynx cancer	0.0233	0.0327	CbGeAlD
Bortezomib—PSMB1—trachea—larynx cancer	0.0228	0.0319	CbGeAlD
Bortezomib—PSMB2—trachea—larynx cancer	0.0222	0.0311	CbGeAlD
Bortezomib—PSMA1—Amino acid and derivative metabolism—HPD—larynx cancer	0.0221	0.0772	CbGpPWpGaD
Bortezomib—PSMD1—Amino acid and derivative metabolism—HPD—larynx cancer	0.022	0.0768	CbGpPWpGaD
Bortezomib—PSMD2—Amino acid and derivative metabolism—HPD—larynx cancer	0.0219	0.0765	CbGpPWpGaD
Bortezomib—PSMB5—thyroid gland—larynx cancer	0.0206	0.0289	CbGeAlD
Bortezomib—CTSG—lymph node—larynx cancer	0.0204	0.0286	CbGeAlD
Bortezomib—PSMA1—lymph node—larynx cancer	0.0196	0.0275	CbGeAlD
Bortezomib—SLC31A1—trachea—larynx cancer	0.0192	0.027	CbGeAlD
Bortezomib—PSMB1—thyroid gland—larynx cancer	0.018	0.0253	CbGeAlD
Bortezomib—PSMB2—thyroid gland—larynx cancer	0.0176	0.0246	CbGeAlD
Bortezomib—PSMB2—Amino acid and derivative metabolism—HPD—larynx cancer	0.0168	0.0585	CbGpPWpGaD
Bortezomib—PSMB1—Amino acid and derivative metabolism—HPD—larynx cancer	0.0168	0.0585	CbGpPWpGaD
Bortezomib—PSMB5—Amino acid and derivative metabolism—HPD—larynx cancer	0.0168	0.0585	CbGpPWpGaD
Bortezomib—PSMB8—Amino acid and derivative metabolism—HPD—larynx cancer	0.0165	0.0577	CbGpPWpGaD
Bortezomib—PSMD1—lymph node—larynx cancer	0.0165	0.0231	CbGeAlD
Bortezomib—SLC31A1—thyroid gland—larynx cancer	0.0152	0.0213	CbGeAlD
Bortezomib—PSMD2—lymph node—larynx cancer	0.0146	0.0204	CbGeAlD
Bortezomib—PSMB8—lymph node—larynx cancer	0.0145	0.0203	CbGeAlD
Bortezomib—PSMB5—lymph node—larynx cancer	0.0128	0.0179	CbGeAlD
Bortezomib—CYP1A1—mouth—larynx cancer	0.0127	0.0178	CbGeAlD
Bortezomib—PSMB1—lymph node—larynx cancer	0.0112	0.0157	CbGeAlD
Bortezomib—PSMB2—lymph node—larynx cancer	0.0109	0.0153	CbGeAlD
Bortezomib—SLC31A1—lymph node—larynx cancer	0.00945	0.0133	CbGeAlD
Bortezomib—CYP1A1—epithelium—larynx cancer	0.00739	0.0104	CbGeAlD
Bortezomib—SLC31A1—Copper homeostasis—TP53—larynx cancer	0.00671	0.0234	CbGpPWpGaD
Bortezomib—CYP1A1—trachea—larynx cancer	0.00653	0.00916	CbGeAlD
Bortezomib—PTGS1—epithelium—larynx cancer	0.00649	0.0091	CbGeAlD
Bortezomib—PTGS1—trachea—larynx cancer	0.00574	0.00805	CbGeAlD
Bortezomib—CYP1A2—thyroid gland—larynx cancer	0.00524	0.00735	CbGeAlD
Bortezomib—CYP1A1—thyroid gland—larynx cancer	0.00517	0.00725	CbGeAlD
Bortezomib—PTGS1—thyroid gland—larynx cancer	0.00454	0.00637	CbGeAlD
Bortezomib—PSMA1—Metabolism—HPD—larynx cancer	0.00407	0.0142	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—HPD—larynx cancer	0.00405	0.0141	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—HPD—larynx cancer	0.00403	0.014	CbGpPWpGaD
Bortezomib—PSMA1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—larynx cancer	0.00392	0.0137	CbGpPWpGaD
Bortezomib—PSMD1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—larynx cancer	0.0039	0.0136	CbGpPWpGaD
Bortezomib—PSMD2—Autodegradation of the E3 ubiquitin ligase COP1—TP53—larynx cancer	0.00388	0.0135	CbGpPWpGaD
Bortezomib—PSMA1—Stabilization of p53—TP53—larynx cancer	0.00386	0.0134	CbGpPWpGaD
Bortezomib—PSMD1—Stabilization of p53—TP53—larynx cancer	0.00384	0.0134	CbGpPWpGaD
Bortezomib—PSMD2—Stabilization of p53—TP53—larynx cancer	0.00382	0.0133	CbGpPWpGaD
Bortezomib—PSMA1—p53-Dependent G1 DNA Damage Response—TP53—larynx cancer	0.00358	0.0125	CbGpPWpGaD
Bortezomib—PSMD1—p53-Dependent G1 DNA Damage Response—TP53—larynx cancer	0.00356	0.0124	CbGpPWpGaD
Bortezomib—PSMD2—p53-Dependent G1 DNA Damage Response—TP53—larynx cancer	0.00354	0.0124	CbGpPWpGaD
Bortezomib—PSMA1—G1/S DNA Damage Checkpoints—TP53—larynx cancer	0.00343	0.012	CbGpPWpGaD
Bortezomib—PSMD1—G1/S DNA Damage Checkpoints—TP53—larynx cancer	0.00342	0.0119	CbGpPWpGaD
Bortezomib—PSMD2—G1/S DNA Damage Checkpoints—TP53—larynx cancer	0.0034	0.0119	CbGpPWpGaD
Bortezomib—CYP1A1—lymph node—larynx cancer	0.00321	0.0045	CbGeAlD
Bortezomib—PSMB1—Metabolism—HPD—larynx cancer	0.00308	0.0107	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—HPD—larynx cancer	0.00308	0.0107	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—HPD—larynx cancer	0.00308	0.0107	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—HPD—larynx cancer	0.00304	0.0106	CbGpPWpGaD
Bortezomib—PSMB5—Autodegradation of the E3 ubiquitin ligase COP1—TP53—larynx cancer	0.00297	0.0104	CbGpPWpGaD
Bortezomib—PSMB1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—larynx cancer	0.00297	0.0104	CbGpPWpGaD
Bortezomib—PSMB2—Autodegradation of the E3 ubiquitin ligase COP1—TP53—larynx cancer	0.00297	0.0104	CbGpPWpGaD
Bortezomib—PSMB8—Autodegradation of the E3 ubiquitin ligase COP1—TP53—larynx cancer	0.00293	0.0102	CbGpPWpGaD
Bortezomib—PSMB1—Stabilization of p53—TP53—larynx cancer	0.00292	0.0102	CbGpPWpGaD
Bortezomib—PSMB2—Stabilization of p53—TP53—larynx cancer	0.00292	0.0102	CbGpPWpGaD
Bortezomib—PSMB5—Stabilization of p53—TP53—larynx cancer	0.00292	0.0102	CbGpPWpGaD
Bortezomib—PSMB8—Stabilization of p53—TP53—larynx cancer	0.00288	0.01	CbGpPWpGaD
Bortezomib—PTGS1—lymph node—larynx cancer	0.00282	0.00396	CbGeAlD
Bortezomib—PSMB1—p53-Dependent G1 DNA Damage Response—TP53—larynx cancer	0.00271	0.00946	CbGpPWpGaD
Bortezomib—PSMB5—p53-Dependent G1 DNA Damage Response—TP53—larynx cancer	0.00271	0.00946	CbGpPWpGaD
Bortezomib—PSMB2—p53-Dependent G1 DNA Damage Response—TP53—larynx cancer	0.00271	0.00946	CbGpPWpGaD
Bortezomib—PSMB8—p53-Dependent G1 DNA Damage Response—TP53—larynx cancer	0.00267	0.00932	CbGpPWpGaD
Bortezomib—PSMB2—G1/S DNA Damage Checkpoints—TP53—larynx cancer	0.0026	0.00907	CbGpPWpGaD
Bortezomib—PSMB1—G1/S DNA Damage Checkpoints—TP53—larynx cancer	0.0026	0.00907	CbGpPWpGaD
Bortezomib—PSMB5—G1/S DNA Damage Checkpoints—TP53—larynx cancer	0.0026	0.00907	CbGpPWpGaD
Bortezomib—PSMB8—G1/S DNA Damage Checkpoints—TP53—larynx cancer	0.00256	0.00894	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle Checkpoints—TP53—larynx cancer	0.00198	0.00692	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle Checkpoints—TP53—larynx cancer	0.00198	0.00689	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle Checkpoints—TP53—larynx cancer	0.00197	0.00685	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—HPD—larynx cancer	0.00161	0.00562	CbGpPWpGaD
Bortezomib—PSMA1—Apoptosis—TP53—larynx cancer	0.00158	0.00553	CbGpPWpGaD
Bortezomib—PSMD1—Apoptosis—TP53—larynx cancer	0.00158	0.0055	CbGpPWpGaD
Bortezomib—PSMD2—Apoptosis—TP53—larynx cancer	0.00157	0.00547	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle Checkpoints—TP53—larynx cancer	0.0015	0.00524	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle Checkpoints—TP53—larynx cancer	0.0015	0.00524	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle Checkpoints—TP53—larynx cancer	0.0015	0.00524	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle Checkpoints—TP53—larynx cancer	0.00148	0.00517	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TP53—larynx cancer	0.0012	0.00419	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TP53—larynx cancer	0.0012	0.00419	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TP53—larynx cancer	0.0012	0.00419	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—TP53—larynx cancer	0.00118	0.00413	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HPD—larynx cancer	0.00114	0.00396	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HPD—larynx cancer	0.00104	0.00363	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HPD—larynx cancer	0.000929	0.00324	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HPD—larynx cancer	0.000854	0.00298	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HPD—larynx cancer	0.000847	0.00295	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HPD—larynx cancer	0.000724	0.00252	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—larynx cancer	0.00058	0.00202	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—larynx cancer	0.000578	0.00201	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—larynx cancer	0.000575	0.002	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HPD—larynx cancer	0.000559	0.00195	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—larynx cancer	0.00044	0.00153	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—larynx cancer	0.00044	0.00153	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—larynx cancer	0.00044	0.00153	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—larynx cancer	0.000434	0.00151	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—larynx cancer	0.000209	0.000727	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—larynx cancer	0.000208	0.000724	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—larynx cancer	0.000207	0.00072	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—larynx cancer	0.000158	0.000551	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—larynx cancer	0.000158	0.000551	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—larynx cancer	0.000158	0.000551	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—larynx cancer	0.000156	0.000543	CbGpPWpGaD
